MoellekenMErfurt-BergeCRonickeM, et al. Predilection sites of pyoderma gangrenosum: retrospective study of 170 clearly diagnosed patients. Int Wound J. 2023;20(10):4227-4234. doi:10.1111/iwj.14323
2.
OrmerodADThomasKSCraigFE, et al. Comparison of the two most commonly used treatments for pyoderma gangrenosum: results of the STOP GAP randomised controlled trial. BMJ. 2015;350:h2958. doi:10.1136/bmj.h2958
3.
BrooklynTNDunnillMGShettyA, et al. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut. 2006;55(4):505-509. doi:10.1136/gut.2005.074815
4.
LinRRMaskan BermudezNBurkeOMKirsnerRS.Clinical characteristics and outcomes of genital pyoderma gangrenosum—a systematic review. J Am Acad Dermatol. 2025;92(6):1387-1389. doi:10.1016/j.jaad.2025.01.084
5.
AhronowitzIHarpJShinkaiK.Etiology and management of pyoderma gangrenosum: a comprehensive review. Am J Clin Dermatol. 2012;13(3):191-211. doi:10.2165/11595240-000000000-00000
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
